Clinical features of generalized lipodystrophy in Turkey: A cohort analysis.
generalized lipodystrophy
metabolic disease
mortality
organ complications
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
09
03
2023
received:
20
01
2023
accepted:
19
03
2023
medline:
5
6
2023
pubmed:
23
3
2023
entrez:
22
3
2023
Statut:
ppublish
Résumé
To describe the Turkish generalized lipodystrophy (GL) cohort with the frequency of each complication and the death rate during the period of the follow-up. This study reports on 72 patients with GL (47 families) registered at different centres in Turkey that cover all regions of the country. The mean ± SD follow-up was 86 ± 78 months. The Kaplan-Meier estimate of the median time to diagnosis of diabetes and/or prediabetes was 16 years. Hyperglycaemia was not controlled in 37 of 45 patients (82.2%) with diabetes. Hypertriglyceridaemia developed in 65 patients (90.3%). The Kaplan-Meier estimate of the median time to diagnosis of hypertriglyceridaemia was 14 years. Hypertriglyceridaemia was severe (≥ 500 mg/dl) in 38 patients (52.8%). Seven (9.7%) patients suffered from pancreatitis. The Kaplan-Meier estimate of the median time to diagnosis of hepatic steatosis was 15 years. Liver disease progressed to cirrhosis in nine patients (12.5%). Liver disease was more severe in congenital lipodystrophy type 2 (CGL2). Proteinuric chronic kidney disease (CKD) developed in 32 patients (44.4%) and cardiac disease in 23 patients (31.9%). Kaplan-Meier estimates of the median time to diagnosis of CKD and cardiac disease were 25 and 45 years, respectively. Females appeared to have a more severe metabolic disease, with an earlier onset of metabolic abnormalities. Ten patients died during the follow-up period. Causes of death were end-stage renal disease, sepsis (because of recurrent intestinal perforations, coronavirus disease, diabetic foot infection and following coronary artery bypass graft surgery), myocardial infarction, heart failure because of dilated cardiomyopathy, stroke, liver complications and angiosarcoma. Standard treatment approaches have only a limited impact and do not prevent the development of severe metabolic abnormalities and early onset of organ complications in GL.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1950-1963Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Akinci B, Sahinoz M, Oral E. Lipodystrophy syndromes: presentation and treatment. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. MA: South Dartmouth; 2000.
Jeru I. Genetics of lipodystrophy syndromes. Presse Med. 2021;50(3):104074.
Hussain I, Patni N, Ueda M, et al. A novel generalized lipodystrophy-associated Progeroid syndrome due to recurrent heterozygous LMNA p.T10I mutation. J Clin Endocrinol Metab. 2018;103(3):1005-1014.
de Andrade NXS, Adiyaman SC, Yuksel BD, et al. Unusual presentations of Lmna-associated lipodystrophy with complex phenotypes and generalized fat loss: when the genetic diagnosis uncovers novel features. AACE Clin Case Rep. 2020;6(2):e79-e85.
Dyment DA, Gibson WT, Huang L, Bassyouni H, Hegele RA, Innes AM. Biallelic mutations at PPARG cause a congenital, generalized lipodystrophy similar to the Berardinelli-Seip syndrome. Eur J Med Genet. 2014;57(9):524-526.
Gautheron J, Lima L, Akinci B, et al. Loss of thymidine phosphorylase activity disrupts adipocyte differentiation and induces insulin-resistant lipoatrophic diabetes. BMC Med. 2022;20(1):95.
Mandel-Brehm C, Vazquez SE, Liverman C, et al. Autoantibodies to Perilipin-1 define a subset of acquired generalized lipodystrophy. Diabetes. 2023;72(1):59-70.
Chiquette E, Oral EA, Garg A, Araujo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes, Metab Syndr Obes. 2017;10:375-383.
Friedman JM. Leptin and the endocrine control of energy balance. Nat Metab. 2019;1(8):754-764.
Akinci B, Oral EA, Neidert A, et al. Comorbidities and survival in patients with lipodystrophy: an international chart review study. J Clin Endocrinol Metab. 2019;104(11):5120-5135.
Akinci B, Meral R, Oral EA. Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities. Curr Diab Rep. 2018;18(12):143.
Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy-an AACE consensus statement. Endocr Pract. 2013;19(1):107-116.
Hussain I, Garg A. Lipodystrophy syndromes. Endocrinol Metab Clin North Am. 2016;45(4):783-797.
Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500-4511.
Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570-578.
Shamsudeen I, Hegele RA. Advances in the care of lipodystrophies. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):152-160.
Akinci B, Onay H, Demir T, et al. Natural history of congenital generalized lipodystrophy: a Nationwide study from Turkey. J Clin Endocrinol Metab. 2016;101(7):2759-2767.
Altay C, Secil M, Demir T, et al. Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy. Diagn Interv Radiol. 2017;23(6):428-434.
American Diabetes Association Professional Practice C. 2. Classification and diagnosis of diabetes: standards of medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S17-S38.
Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol In adults (adult treatment panel III). JAMA. 2001;285(19):2486-2497.
Saydam O, Ozgen Saydam B, Adiyaman CS, et al. Diabetic foot ulcers: a neglected complication of lipodystrophy. Diabetes Care. 2020;43(10):e149-e151.
Akinci G, Topaloglu H, Demir T, et al. Clinical spectra of neuromuscular manifestations in patients with lipodystrophy: a multicenter study. Neuromuscul Disord. 2017;27(10):923-930.
Akinci G, Topaloglu H, Akinci B, et al. Spectrum of clinical manifestations in two young Turkish patients with congenital generalized lipodystrophy type 4. Eur J Med Genet. 2016;59(6-7):320-324.
Nilay G, Kutlu T, Tekant GT, et al. Congenital generalized lipodystrophy: the evaluation of clinical follow-up findings in a series of five patients with type 1 and two patients with type 4. Eur J Med Genet. 2020;63(4):103819.
Karhan AN, Zammouri J, Auclair M, et al. Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia. Eur J Endocrinol. 2021;185(6):841-854.
Brown RJ, Oral EA, Cochran E, et al. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Endocrine. 2018;60(3):479-489.
Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol. 2013;59(1):131-137.
Chait A. Hypertriglyceridemia. Endocrinol Metab Clin North Am. 2022;51(3):539-555.
Rajab A, Straub V, McCann LJ, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 2010;6(3):e1000874.
Sanon VP, Handelsman Y, Pham SV, Chilton R. Cardiac manifestations of congenital generalized lipodystrophy. Clin Diabetes. 2016;34(4):181-186.
Hill MM, Bastiani M, Luetterforst R, et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell. 2008;132(1):113-124.
Parton RG. Caveolae: structure, function, and relationship to disease. Annu Rev Cell Dev Biol. 2018;34:111-136.
Taniguchi T, Maruyama N, Ogata T, et al. PTRF/Cavin-1 deficiency causes cardiac dysfunction accompanied by cardiomyocyte hypertrophy and cardiac fibrosis. PLoS One. 2016;11(9):e0162513.
Patni N, Vuitch F, Garg A. Postmortem findings in a young man with congenital generalized lipodystrophy, type 4 due to CAVIN1 mutations. J Clin Endocrinol Metab. 2019;104(3):957-960.
Eldin AJ, Akinci B, da Rocha AM, et al. Cardiac phenotype in familial partial lipodystrophy. Clin Endocrinol. 2021;94(6):1043-1053.
Kwapich M, Lacroix D, Espiard S, et al. Cardiometabolic assessment of Lamin a/C gene mutation carriers: a phenotype-genotype correlation. Diabetes Metab. 2019;45(4):382-389.
Lee HL, Waldman MA, Auh S, et al. Effects of metreleptin on proteinuria in patients with lipodystrophy. J Clin Endocrinol Metab. 2019;104(9):4169-4177.
Javor ED, Moran SA, Young JR, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89(7):3199-3207.
Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 2000;85(5):1776-1782.
Guaraldi G, Murri R, Orlando G, et al. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS. 2008;22(7):577-585.
Gavin KM, Bessesen DH. Sex differences in adipose tissue function. Endocrinol Metab Clin North Am. 2020;49(2):215-228.
Bluher M. Importance of estrogen receptors in adipose tissue function. Mol Metab. 2013;2(3):130-132.
Wells JC. Sexual dimorphism of body composition. Best Pract Res Clin Endocrinol Metab. 2007;21(3):415-430.
Kelsey MM, Zeitler PS. Insulin resistance of puberty. Curr Diab Rep. 2016;16(7):64.
Shalitin S, Phillip M. Role of obesity and leptin in the pubertal process and pubertal growth-a review. Int J Obes Relat Metab Disord. 2003;27(8):869-874.
Van Maldergem L, Magre J, Khallouf TE, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002;39(10):722-733.
Lima JG, Nobrega LHC, Lima NN, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS One. 2018;13(6):e0199052.
Gupta N, Asi N, Farah W, et al. Clinical features and management of non-HIV-related lipodystrophy in children: a systematic review. J Clin Endocrinol Metab. 2017;102(2):363-374.
Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment. Medicine. 2010;89(4):245-250.
Cook K, Adamski K, Gomes A, et al. Effects of metreleptin on patient outcomes and quality of life in generalized and partial lipodystrophy. J Endocr Soc. 2021;5(4):bvab019.